2008

Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression

David A. Rosen  
Washington University School of Medicine in St. Louis

Jerome S. Pinkner  
Washington University School of Medicine in St. Louis

Jennifer M. Jones  
Washington University School of Medicine in St. Louis

Jennifer N. Walker  
Washington University School of Medicine in St. Louis

Steven Clegg  
University of Iowa

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

https://digitalcommons.wustl.edu/open_access_pubs/2437

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Utilization of an Intracellular Bacterial Community Pathway in *Klebsiella pneumoniae* Urinary Tract Infection and the Effects of FimK on Type 1 Pilus Expression

David A. Rosen, Jerome S. Pinkner, Jennifer M. Jones, Jennifer N. Walker, Steven Clegg and Scott J. Hultgren


Updated information and services can be found at:
http://iai.asm.org/content/76/7/3337

**REFERENCES**

These include:

This article cites 62 articles, 35 of which can be accessed free at:  
http://iai.asm.org/content/76/7/3337#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article),  
more»

Information about commercial reprint orders:  
http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to:  
http://journals.asm.org/site/subscriptions/
Utilization of an Intracellular Bacterial Community Pathway in Klebsiella pneumoniae Urinary Tract Infection and the Effects of FimK on Type 1 Pilus Expression

David A. Rosen, Jerome S. Pinkner, Jennifer M. Jones, Jennifer N. Walker, Steven Clegg, and Scott J. Hultgren

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, and Department of Microbiology, College of Medicine, University of Iowa, Iowa City, Iowa 52242

Received 22 January 2008/Returned for modification 8 March 2008/Accepted 7 April 2008

Klebsiella pneumoniae is an important cause of urinary tract infection (UTI), but little is known about its pathogenesis in vivo. The pathogenesis of the K. pneumoniae cystitis isolate TOP52 was compared to that of the uropathogenic Escherichia coli (UPEC) isolate UTI89 in a murine cystitis model. Bladder and kidney titers of TOP52 were lower than those of UTI89 at early time points but similar at later time points. TOP52, like UTI89, formed biofilm-like intracellular bacterial communities (IBCs) within the murine bladder, albeit at significantly lower levels than UTI89. Additionally, filamentation of TOP52 was observed, a process critical for UTI89 evasion of neutrophil phagocytosis and persistence in the bladder. Thus, the IBC pathway is not specific to UPEC alone. We investigated if differences in type 1 pilus expression may explain TOP52’s early defect in vivo. The type 1 pilus operon is controlled by recombinase-mediated (fimE, fimB, and fimX) phase variation of an invertible promoter element. We found that K. pneumoniae carries an extra gene of unknown function at the 3′ end of its type 1 operon, fimK, and the genome lacks the recombinase fimX. A deletion mutant of fimK was constructed, and TOP52 ΔfimK had higher titers and formed more IBCs in the murine cystitis model than wild type. The loss of fimK or expression of E. coli fimX from a plasmid in TOP52 resulted in a phase-on population and higher expression levels of type 1 pilin and gave TOP52 the ability to form type 1-dependent biofilms. Complementation with pUF1 produced a higher type 1 pilus expression and biofilm formation of TOP52 ΔfimK and decreased UTI89 biofilm formation. Thus, K. pneumoniae appears programmed for minimal expression of type 1 pili, which may explain, in part, why K. pneumoniae is a less prevalent etiologic agent of UTI than UPEC.

Nearly 13 million women get urinary tract infections (UTIs) per year in the United States alone, and more than half of all women will experience a UTI during their lifetimes (16, 23, 28, 29, 52). These infections often recur, and over half of all recurrent episodes are caused by the same bacterial strain as the initial infection (17, 54). Uropathogenic Escherichia coli (UPEC) is the most common etiologic agent, responsible for 80 to 85% of community-acquired UTIs (51). However, there are several other significant uropathogens, including Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis (49).

K. pneumoniae causes up to 5% of community-acquired UTIs and is significantly more common in diabetic patients and in the nosocomial setting (26, 36, 50). The urinary tract is the most common site of Klebsiella infection, although it may be better recognized as a cause of pneumonia in compromised hosts (7). Over the past 25 years, there has been a substantial increase in the spread of drug-resistant strains of Klebsiella, particularly those producing extended-spectrum β-lactamases (42). K. pneumoniae encodes type 1 pili, and its corresponding fim operon is highly homologous to that of E. coli (14, 22). As with E. coli, expression of the fim operon is phase variable, controlled by an invertible promoter element, fimS, fimE, and fimB are recombinase genes in the type 1 pilus gene cluster that mediates the phase switching of fimS (33). fimX is not part of the fim gene cluster but encodes a recombinase that is also important in fimS phase switching in vivo (4, 25). ON-phase K. pneumoniae displays superior in vitro binding to ciliated hamster tracheal epithelial cells and rat bladder epithelial cells (12, 15) and in vivo infection of the rat urinary tract (13) compared to OFF-phase organisms. It has also been shown that infection of the mouse urinary tract leads to a population shift favoring organisms expressing type 1 pili (37).

UPEC strains utilize a multistep pathogenic pathway during human and murine infection in which the bacteria invade bladder facet cells and replicate intracellularly (1, 19, 30, 44, 53). Almost all UPEC strains express type 1 pili, which consist of thin-tipped fibrillae attached to thicker pilus rods (5). Genes essential for UPEC type 1 pilus biogenesis are organized in the fim operon, with fimH encoding the adhesin that recognizes mannosylated uropilins on the luminal surface of facet cells (63). Binding of UPEC to the host cell, possibly through β1 and α3 integrins, induces a cascade of signaling events that leads to bacterial internalization (11, 38, 39). Within the superficial facet cells of the bladder, piliated UPEC bacteria replicate to form intracellular bacterial communities (IBCs) with biofilm-like properties (1, 62). IBCs are transient, and the bacteria ultimately flux out of epithelial cells, some adopting a filamentous morphology. These long filaments evade engulfment by neutrophils and are necessary for persistence in the murine cystitis model (31). UPEC is also able to...
form quiescent intracellular reservoirs (QIRs) that can persist for several weeks protected from antibiotics and seemingly undetected by the host immune system (44, 46, 57). It has not yet been determined whether non-UPEC uropathogens, such as *K. pneumoniae*, utilize an intracellular bladder niche during infection. In this study we investigated the pathogenesis of *K. pneumoniae* in the murine cystitis model compared to UPEC. We discovered interesting differences in the pathogenic pathway of *K. pneumoniae* that were related to the expression of type 1 pilis.

**MATERIALS AND METHODS**

**Bacterial strains and culture conditions.** A complete list of bacterial strains and plasmids used in this study can be found in Table 1. Clinical strains used include UTI89, a UPEC cystitis isolate (44), and TOP52 1721 (abbreviated TOP52), a *K. pneumoniae* cystitis isolate. TOP52 was isolated from the urine of a 26-year-old woman with acute cystitis from a previous UTI study (53). After successful completion of antibiotic therapy and negative follow-up urine cultures, this patient developed recurrent cystitis with the same strain of *K. pneumoniae*, as determined by restriction fragment length polymorphism analysis. Bacteria were cultured at 37°C in Luria-Bertani (LB) broth containing, as appropriate, 20 μg/ml chloramphenicol, 50 μg/ml kanamycin, and arabinose as indicated below.

TOP52 and UTI89 mutant construction and complementation. Targeted deletion mutants of *fimK* and *fimA-fimH* in the *K. pneumoniae* isolate TOP52 were constructed with the pKOV vector as described previously (35). Flanking sequences of approximately 1,000 bp on each side of the targeted gene were amplified with the primers indicated in Table 2 and cloned into pKOV. Potential knockouts were screened by PCR, and the knockout region was sequenced. Growth curves were done for all mutant strains and showed no differences in growth compared to the wild type.

**Urine collection.** Bacterial strains were used to inoculate 8-week-old female C3H/HeN mice (National Cancer Institute) by transurethral catheterization as previously described (43). Static cultures (25 ml) were started from freezer stocks and grown at 37°C for 18 h and then subcultured at 1:250 into 25 ml of fresh medium. These cultures were then grown statically at 37°C for 18 h and centrifuged for 5 min at 5,800 rpm, and the resultant pellet was resuspended in phosphate-buffered saline (PBS) and diluted to approximately 2 × 10^7 CFU/ml. Fifty milliliters of this suspension was used to infect each mouse with an inoculum of 1 × 10^7 to 2 × 10^7 CFU. All studies were approved by the Animal Studies Committee at Washington University School of Medicine.

**TABLE 1. Bacterial strains and plasmids**

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Description</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTI89</td>
<td>UPEC cystitis isolate</td>
<td>44</td>
</tr>
<tr>
<td>UTI89 ΔfimA-fimH</td>
<td>Knockout of fimA-fimH in UTI89</td>
<td>This study</td>
</tr>
<tr>
<td>TOP52 1721</td>
<td><em>K. pneumoniae</em> cystitis isolate</td>
<td>53; also this study</td>
</tr>
<tr>
<td>TOP52 ΔfimK</td>
<td>Knockout of fimK in TOP52</td>
<td>This study</td>
</tr>
<tr>
<td>TOP52 ΔfimA-fimH</td>
<td>Knockout of fimA-fimH in TOP52</td>
<td>This study</td>
</tr>
</tbody>
</table>

**Plasmids**

<table>
<thead>
<tr>
<th>Vector</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pBAD33</td>
<td>Empty expression vector; arabinose inducible; Cm'</td>
<td>24</td>
</tr>
<tr>
<td>pfinK</td>
<td>TOP52 fimK expression vector; arabinose inducible; Cm'</td>
<td>This study</td>
</tr>
<tr>
<td>pfinX</td>
<td>UTI89 fimX expression vector; arabinose inducible; Cm'</td>
<td>25</td>
</tr>
</tbody>
</table>

**TABLE 2. Primer sequences**

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Primer use</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>NotIFimKF1</td>
<td>Amplify 1-kb fimK 5' flank region</td>
<td>5'CGGTAACGCGGCGCGCAGATCCGGAAAGACGTACAC-3'</td>
</tr>
<tr>
<td>HindIIIIFimKR2</td>
<td>Amplify 1-kb fimK 5' flank region</td>
<td>5'AAACAGGCTGAATCAGCCACCAACACGAC-3'</td>
</tr>
<tr>
<td>SallFimKR4</td>
<td>Amplify 1-kb fimK 3' flank region</td>
<td>5'CATAAGCTTAGAAAAGCGCACCGGTTA-3'</td>
</tr>
<tr>
<td>3FimKCheckF</td>
<td>Check TOP52 fimK</td>
<td>5'CCATATTAAGGCGAGTGTGGACTAC-3'</td>
</tr>
<tr>
<td>3FimKCheckR</td>
<td>Check TOP52 fimK</td>
<td>5'AAAGTCGACCCGCAAGATACGCGTTTGAT-3'</td>
</tr>
<tr>
<td>NotIFimF1</td>
<td>Amplify 1-kb fimA 5' flank region</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>BamHIIFimF2</td>
<td>Amplify 1-kb fimA 5' flank region</td>
<td>5'CTGTTTGTGCGCGATGCTTTCC-3'</td>
</tr>
<tr>
<td>SallFimR4</td>
<td>Amplify 1-kb fimA 3' flank region</td>
<td>5'GTGGATATTCAGCTACACG-3'</td>
</tr>
<tr>
<td>3FimCheckF</td>
<td>Check TOP52 ΔfimA-fimH</td>
<td>5'AAACAGGCTGAATCAGCCACCAACACGAC-3'</td>
</tr>
<tr>
<td>3FimCheckR</td>
<td>Check TOP52 ΔfimA-fimH</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>3FimKcompF</td>
<td>Amplify TOP52 fimK for cloning into pBAD</td>
<td>5'AAAGTCGACCCGCAAGATACGCGTTTGAT-3'</td>
</tr>
<tr>
<td>3FimKcompR</td>
<td>Amplify TOP52 fimK for cloning into pBAD</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>pBADF</td>
<td>Check pBAD clones</td>
<td>5'CTGTTTGTGCGCGATGCTTTCCG-3'</td>
</tr>
<tr>
<td>pBADR</td>
<td>Check pBAD clones</td>
<td>5'AAACAGGCTGAATCAGCCACCAACACGAC-3'</td>
</tr>
<tr>
<td>UTI89fimA-H KO F</td>
<td>Knockout fimA-fimH in UTI89</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>UTI89fimA-H KO R</td>
<td>Knockout fimA-fimH in UTI89</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>UTI89fimA-HcheckF</td>
<td>Check UTI89 fimA-fimH</td>
<td>5'AAACAGGCTGAATCAGCCACCAACACGAC-3'</td>
</tr>
<tr>
<td>UTI89fimA-HcheckR</td>
<td>Check UTI89 fimA-fimH</td>
<td>5'CCAACCGCATCCTCTTCCG-3'</td>
</tr>
<tr>
<td>2KlebphaseF</td>
<td>Amplify fimS region for phase assay</td>
<td>5'CTGTTTGTGCGCGATGCTTTCCG-3'</td>
</tr>
<tr>
<td>2KlebphaseR</td>
<td>Amplify fimS region for phase assay</td>
<td>5'CTGTTTGTGCGCGATGCTTTCCG-3'</td>
</tr>
</tbody>
</table>

**Mouse infections.** Bacterial strains were used to inoculate 8-week-old female C3H/HeN mice (National Cancer Institute) by transurethral catheterization as previously described (43). Static cultures (25 ml) were started from freezer stocks and grown at 37°C for 18 h and then subcultured at 1:250 into 25 ml of fresh medium. These cultures were then grown statically at 37°C for 18 h and centrifuged for 5 min at 5,800 rpm, and the resultant pellet was resuspended in phosphate-buffered saline (PBS) and diluted to approximately 2 × 10^7 CFU/ml. Fifty milliliters of this suspension was used to infect each mouse with an inoculum of 1 × 10^7 to 2 × 10^7 CFU. All studies were approved by the Animal Studies Committee at Washington University School of Medicine.

**Downloaded from http://iai.asm.org/ on March 18, 2014 by Washington University in St. Louis**
Organ titers, gentamicin protection assays, and IBC enumeration. To quantify bacteria present in mouse organs, bladders and kidneys were aseptically harvested at the indicated times postinfection, homogenized in PBS, serially diluted, and plated onto LB agar plates. Luminal and intracellular bacteria were quantified using an ex vivo gentamicin protection assay as previously described (32). For ex vivo enumeration of IBCs, infected bladders were harvested at the times indicated in the figure legends, bisected, splayed, washed with PBS, fixed with 3% paraformaldehyde for 60 min at room temperature, and lacZ stained as previously described (32). IBCs were visualized and counted using an Olympus SZX12 dissecting microscope (Olympus America).

Histology and immunohistochemistry. Infected mouse bladders were aseptically removed, fixed in neutral buffer formalin, and paraffin embedded, and sections were stained with hematoxylin and eosin. For immunohistochemistry, unstained slides were deparaffinized, washed in filter-sterilized PBS, blocked in 1% bovine serum albumin–0.3% Triton X-100 for 1 h at room temperature, and stained as previously described (32). Titrations and were prepared for electron microscopy (EM) as follows. Bacteria were absorbed onto Formvar-carbon-coated copper grids for 1 min. Grids were washed in distilled water and stained with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 min. Excess liquid was gently wicked off, and grids were allowed to air dry. Samples were viewed on a JEOL 1200EX transmission EM (JEOL USA) at an accelerating voltage of 80 kV, and representative images are shown.

Biofilm assays. Bacteria were grown in LB broth in wells of microtiter plates with the presence of 0.1% arabinose (for complementation in UTI89) or 0.01% arabinose (for complementation in TOP52), as appropriate. After 48 h of growth at room temperature, wells were rinsed and stained with crystal violet, and biofilms were quantified as previously described (47). Resulting graphs compare means ± standard errors of the means of two independent experiments, each with duplicate plates.

Statistical analysis. Continuous variables were compared using a Mann-Whitney U test since these variables were not normally distributed. For biofilm data, means of multiple plates from two independent experiments were compared, and t tests were performed. All tests were two tailed, and a P value less than 0.05 was considered significant. Analyses were performed using GraphPad Prism (version 4.03; GraphPad Software).

Nucleotide sequence accession number. The TOP52 fimK nucleotide sequence has been deposited in the GenBank database under accession number EU315065.

RESULTS

TOP52 compared to UTI89 in a murine cystitis model. To contrast urinary tract infections of K. pneumoniae and E. coli, C3H/HeN female mice were inoculated by transurethral catheterization with 10^7 CFU of TOP52, a K. pneumoniae cystitis isolate, or 10^7 CFU of UTI89, an E. coli cystitis isolate. Inoculations with less than 10^7 CFU of TOP52 did not result in consistent infection in the mouse model (data not shown).
Bladders and kidneys were harvested at various time points postinoculation, and bacterial titers were determined. In the bladder (Fig. 1A), TOP52 had significantly lower titers than UTI89 at both the 6-h ($P_{H11021} = 0.0001$) and 24-h ($P_{H11005} = 0.0487$) time points. At later time points, TOP52 and UTI89 titers were similar in bladders. At 2 weeks postinoculation, the distributions of TOP52 and UTI89 titers were similar in bladders. In the kidney (Fig. 1B), TOP52 had slightly lower titers than UTI89 at 6 h ($P_{H11005} = 0.0304$); however, it had similar or higher titers than UTI89 in the kidney at all other time points tested.

It has been shown that UPEC bacteria invade bladder epithelial cells during infection. The ability of K. pneumoniae to invade bladder epithelial cells during UTI was investigated using gentamicin protection assays of the bladder performed at 6 h and 24 h postinoculation. At each time point, luminal bacteria were collected by successive bladder washes prior to gentamicin treatment. TOP52, like UTI89, had substantial intracellular populations of bacteria at both 6 and 24 h postinoculation. At 6 h (Fig. 1C), TOP52 had significantly more intracellular bacteria than luminal bacteria ($P_{H11005} = 0.0087$), as did UTI89 ($P = 0.0022$). By 24 h (Fig. 1D), the number of intracellular bacteria was similar to the number of extracellular bacteria for both TOP52 and UTI89. However, the numbers of both luminal and intracellular TOP52 bacteria were significantly lower than the respective UTI89 levels at 6 h ($P_{H11005} = 0.0022$). Thus, TOP52 may be defective in adherence and/or invasion of the bladder urothelium early in infection relative to UTI89.

These data demonstrate that the K. pneumoniae cystitis isolate TOP52 is able to infect the bladder and kidneys of mice in the murine cystitis model. However, TOP52 has significantly reduced titers early in infection compared to the E. coli cystitis isolate, UTI89. Similar to UTI89, there also appears to be a significant intracellular population of TOP52 early in infection.

**TOP52 progresses through an IBC pathway.** Histology was performed on TOP52 bladders at 6 h postinoculation, and numerous sections were analyzed in order to further characterize the intracellular population of TOP52. Large IBCs were found in TOP52-infected bladders (Fig. 2A). These biofilm-like communities, found within superficial bladder facet cells, appeared morphologically identical to those found in UTI89-infected bladders (Fig. 2B). Immunohistochemistry staining with Klesbsiella-specific antibodies confirmed that these IBCs were composed of K. pneumoniae (data not shown). Staining with antibodies against type 1 pili confirmed that type 1 pili are expressed within TOP52 IBCs and UTI89 IBCs (green areas in Fig. 2C and D, respectively), similar to what has been reported previously for UTI89 (62). At 24 h postinoculation, filamentous bacteria, another hallmark of the IBC pathway, were found in urine samples from both TOP52-infected (Fig. 2E) and UTI89-infected (Fig. 2F) mice.

IBCs were visualized and quantified by lacZ staining of whole mounted, fixed bladders at 6 and 24 h postinoculation of TOP52 or UTI89 (Fig. 2G). TOP52 had significantly fewer IBCs than UTI89 at both the 6-h ($P_{H11005} = 0.0012$) and 24-h ($P_{H11005} = 0.0221$) time points. Taken together, these data demonstrate that TOP52 progresses through an IBC pathogenic pathway. TOP52, however, forms fewer IBCs than UTI89 early in infection.

The fim operon of TOP52 contains fimK, and TOP52 ΔfimK has higher bacterial titers in vivo. We investigated whether the differences in bacterial burden and IBC formation between TOP52 and UTI89 observed at early time points in infection may, in part, relate to the expression of type 1 pili. We found
that while *K. pneumoniae* encodes intact *fimB* and *fimE* recombinases important in mediating phase variation of the invertible promoter element, it lacks *fimX*. Compared to UTI89, the *fim* operon of TOP52 also contains an extra gene of unknown function, *fimK* (Fig. 3A). *fimK* was also found to be present immediately downstream of *fimH* in both of the other strains of *K. pneumoniae* for which the sequence of this region was available (22, 41). The sequence of the 1,410-bp open reading frame of *fimK* (GenBank accession number EU315065) showed no homology to sequenced bacterial genes. However, the carboxy-terminus contained an EAL domain, a domain which has previously been implicated in cleavage of the second messenger cyclic-di-GMP (8, 58, 60).

A deletion mutant of *fimK* was constructed, and the ability of TOP52 ∆*fimK* to colonize and form IBCs was investigated in the murine cystitis model. At 6 h postinoculation, TOP52 ∆*fimK* had significantly higher titers in bladder (Fig. 3B) and kidney (Fig. 3C) than wild-type TOP52 (*P* = 0.0112 and *P* = 0.0240, respectively). The *fimK* gene was cloned downstream of an arabinose-inducible promoter to make p*fimK* for complementation studies. TOP52 ∆*fimK*/*p fimK* had significantly lower titers in bladder and kidney than the empty vector control, TOP52 ∆*fimK*/*pBAD* (*P* = 0.0006 and *P* = 0.0091, respectively).

*lacZ* staining of whole mounted, fixed bladders was performed to determine if the deletion of *fimK* had a quantitative effect on IBC formation (Fig. 3D). While wild-type TOP52 formed a mean of 1.8 IBCs per bladder, TOP52 ∆*fimK* formed 4.6 (∆*fimK*/*pBAD (0.0312). The TOP52 ∆*fimK*/*pBAD* vector control formed a mean of 5.7 IBCs per bladder while TOP52 ∆*fimK*/*p fimK* formed 3.3 IBCs per bladder (*P* = 0.0939). These data suggest that loss of *fimK* results in higher bacterial titers, greater numbers of IBCs, and overall more-efficient bladder infection.

TOP52 ∆*fimK* and TOP52/*p fimX* have higher expression levels of type 1 pili. We hypothesized that the low bladder colonization and IBC formation levels of TOP52 compared to UTI89 may be related to type 1 pilus expression. Possible differences in type 1 pilus expression could potentially result from the lack of the *fimX* recombinase or the presence of the *fimK* gene in TOP52. The higher titers in bladder and increased abundance of IBCs observed with the loss of *fimK* could potentially be explained by a higher level of type 1 pilus expression. Thus, the effects of *fimK* loss or *fimX* addition on type 1 pilus expression were investigated. Levels of the major type 1 pilus subunit, FimA, were monitored by whole-cell immunoblotting using anti-FimA antibodies. Cells were normalized by OD<sub>600</sub>, and Coomassie staining was used to verify similar levels of protein in each lane. In addition, the orientation of the *fimS* promoter was analyzed in phase assays to test if the loss of *fimK* or the addition of *fimX* affects type 1 pilus expression (Fig. 4). TOP52 ∆*fimK* produced a larger FimA band than TOP52 as determined by immunoblot analysis. Complementation of TOP52 ∆*fimK* with *p fimK* reduced the size of the FimA band to close to the wild-type level. Moreover, the addition of *fimX* in TOP52 also led to the production of a larger FimA band than that produced by the vector control. As a control, *fimA-fimH* was deleted in TOP52. This negative-control strain, TOP52 ∆*fimA-fimH*, did not produce a FimA band.

Phase assays were performed in which the *fimS* invertible region was amplified by PCR and digested using a restriction endonuclease to determine the orientation of the *fim* operon promoter. TOP52 ∆*fimK* had a larger proportion of phase-ON
cells than TOP52, which was primarily phase OFF. This phenotype could be partially complemented using \( \text{pfimK} \). TOP52 \( \Delta\text{fimK}/\text{pfimK} \) had a slightly larger phase-OFF population than the TOP52 \( \Delta\text{fimK}/\text{pBAD} \) vector control. Expression of \( \text{fimX} \) in TOP52 resulted in a significant shift in the population to the phase-ON position compared to the TOP52/\text{pBAD} vector control, which was primarily phase OFF. The negative control, TOP52 \( \Delta\text{fimA}\text{-fimH} \), did not yield a PCR product because a portion of the corresponding DNA had been deleted.

For semiquantitative measures of type 1 pilus expression in these \( K. pneumoniae \) strains, we performed antigenic titration assays (Table 3). This assay tests the ability of various dilutions of type 1 pilus-monospecific antiserum to agglutinate bacteria. For wild-type TOP52, only dilutions of antibody up to 1:160 caused agglutination, while TOP52 \( \Delta\text{fimK} \) agglutinated at levels up to 1:2,560, indicating much higher expression of type 1 pili in TOP52 \( \Delta\text{fimK} \). While the vector control resulted in similar antibody titers, complementation of TOP52 \( \Delta\text{fimK} \) with \( \text{pfimK} \) resulted in a titer of 1:80 with arabinose induction, thus fully decreasing type 1 piliation down to levels similar to wild type. The negative control TOP52 \( \Delta\text{fimA}\text{-fimH} \), as expected, did not agglutinate even with the highest concentration of type 1 antiserum. It should also be noted that all strains had similar titers when antiserum to type 3 pili was used (data not shown), indicating that \( \text{fimK} \) does not affect expression of type 3 pili.

Additionally, negative-stain EM was performed to visualize type 1 pili in the different strains (Fig. 5). Wild-type TOP52 showed low to moderate levels of type 1 piliation, while TOP52 \( \Delta\text{fimA}\text{-fimH} \) was exclusively bald. TOP52 \( \Delta\text{fimK} \) and TOP52 \( \Delta\text{fimK}/\text{pBAD} \) had a dramatic shift in the proportion of heavily type 1-piliated bacteria. This hyperpiliation phenotype was reduced in TOP52 \( \Delta\text{fimK}/\text{pfimK} \). TOP52/\text{pfimX} also displayed higher levels of piliation than the TOP52/\text{pBAD} vector control.

These data suggest that \( \text{fimK} \) inhibits type 1 piliation in TOP52 and that the addition of \( \text{fimX} \) can increase piliation. This was demonstrated at the transcriptional level in which loss of \( \text{fimK} \) or the addition of \( \text{fimX} \) resulted in an increased population of phase-ON bacteria and increased amounts of FimA. Wild-type TOP52 was primarily phase OFF, with inherently low production of type 1 pili possibly hindering its ability to cause infection in the urinary tract. The presence of \( \text{fimK} \) and lack of \( \text{fimX} \) in TOP52 may, in part, account for the significantly reduced bacterial titers early in infection compared to those in UT189.

\( \text{fimK} \) and \( \text{fimX} \) affect in vitro biofilm formation. To determine if the loss of \( \text{fimK} \) or the gain of \( \text{fimX} \) has effects on type 1-dependent biofilm formation, which may be important in vivo, TOP52 biofilm assays were performed (Fig. 6A). Crystal violet was used to stain biofilms, and the amount of biofilm was quantified by measuring absorbance at OD\(_{600}\). Wild-type TOP52 failed to make biofilm in this assay after 48 h as did the negative control, TOP52 \( \Delta\text{fimA}\text{-fimH} \). TOP52 \( \Delta\text{fimK} \), however, formed biofilm under the same conditions. TOP52 \( \Delta\text{fimK}/\text{pBAD} \) vector control, which was unable to form biofilm (\( P = 0.0128 \)). Thus, complementation of TOP52 \( \Delta\text{fimK} \) with \( \text{pfimK} \) significantly reduced its ability to form biofilm. Expression of the recombinase \( \text{fimX} \) on a plasmid also conferred TOP52 with the ability to form biofilm. TOP52/\text{pfimX} made significantly more biofilm than the TOP52/\text{pBAD} vector control, which was unable to form biofilm (\( P = 0.0002 \)). TOP52 \( \Delta\text{fimA}\text{-fimH}/\text{pfimX} \) did not form biofilm (data not shown), verifying that biofilm formation required type 1 pilus expression.

Wild-type TOP52 was transformed with \( \text{pfimK} \) in order to determine if \( \text{fimK} \) expression would also reduce UT189 biofilm formation (Fig. 6B). Wild-type UT189 formed a robust biofilm after 48 h. The negative control, UT189 \( \Delta\text{fimA}\text{-fimH} \), was unable to form biofilm. Expression of \( \text{pfimK} \) in UT189 decreased biofilm formation compared to that of the UT189/\text{pBAD} vector control (\( P = 0.0022 \)).

While wild-type TOP52 is unable to form type 1 pilus-dependent biofilms, loss of \( \text{fimK} \) or addition of \( \text{fimX} \) transforms a non-biofilm former into a biofilm producer. Interestingly, these

<table>
<thead>
<tr>
<th>Sample</th>
<th>FimA Immunoblot</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOP52</td>
<td>Densitometry: 50</td>
</tr>
<tr>
<td>TOP52/ΔfimK</td>
<td>4</td>
</tr>
<tr>
<td>TOP52/ΔfimK/ΔfimX</td>
<td>99</td>
</tr>
<tr>
<td>TOP52/ΔfimX</td>
<td>124</td>
</tr>
<tr>
<td>TOP52/ΔfimK/pBAD</td>
<td>63</td>
</tr>
<tr>
<td>TOP52/ΔfimK/ΔfimH</td>
<td>58</td>
</tr>
<tr>
<td>TOP52/ΔfimK/ΔfimX/pBAD</td>
<td>179</td>
</tr>
</tbody>
</table>

*Titers are the reciprocal of the highest dilution of serum causing visible agglutination after 5 min. Titers represent the median of three independent experiments.*
data suggest that fimK acts as an inhibitory factor for biofilm formation in both TOP52 and UTI89, likely by affecting changes in expression of type 1 pili. Thus, fimK likely affects type 1 pili or biofilm regulatory pathways that are conserved in both K. pneumoniae and E. coli.

DISCUSSION

Even though K. pneumoniae is the second most common cause of gram-negative UTI, few studies have analyzed the pathogenesis of K. pneumoniae in a UTI model. In this study, we infected mice with TOP52, a K. pneumoniae cystitis isolate, and found that, early in infection, it had lower titers than UTI89, a UPEC strain, in bladder and kidney. The reason for this early deficiency is likely related, in part, to the type 1 pilation state of TOP52. TOP52 carries the gene fimK, which acts to reduce type 1 pilation. Additionally, TOP52 lacks fimX, a recombinase gene able to increase type 1 pilation. These factors may predispose K. pneumoniae to be a less-effective uropathogen than UPEC.

The few bacteria that get introduced into the host bladder (3, 6, 27) are less likely to adhere to or invade the bladder surface because of less type 1 piliation. A less-piliated organism is presumably at a significant disadvantage upon entrance into the bladder and is less likely to survive to initiate significant infection in the host. In addition, it should be noted that while we analyzed the expression of K. pneumoniae type 1 pili, it is not clear that their function is the same as that of E. coli type 1 pili. More work needs to be done to determine if there are structural or functional differences between K. pneumoniae and UPEC type 1 pili that may also affect UTI pathogenesis.

TOP52 was able to form biofilm-like IBCs in the bladder; however, it made significantly fewer IBCs than UTI89. Interestingly, despite this defect, TOP52 titers are similar to those of UTI89 at later time points in infection. TOP52 may be able to persist at a relatively constant level throughout the course of infection while UTI89 infection levels decrease to the level of TOP52. This could be due to the influence of the host inflammatory responses to each uropathogen. Alternatively, there may be a lag in K. pneumoniae infection due to type 1 pilus-dependent experiments, each with duplicate plates. Error bars represent standard errors of the means.
expression or other factors. Bacterial filamentation has been shown to be important for UPEC persistence in the murine cystitis model (31). It should be noted that no obvious differences in the levels of bacterial filamentation were observed in 24-h urine samples of UTI89-infected and TOP52-infected mice; however, quantitative measurements of filamentation were not performed. Ultimately, both UTI89 and TOP52 were able to effectively persist in similar ways in the murine cystitis model with an inoculum of 10^9 CFU. In humans, relatively few bacteria are introduced into the bladder, and if K. pneumoniae has a lower probability of forming IBCs than UPEC, then K. pneumoniae may be cleared more efficiently.

This is the first account of a non-UPEC uropathogen forming IBCs in the bladder. Thus, the ability to form IBCs is not specific to UPEC. The IBC pathway may be a conserved mechanism by which many uropathogens evade the host innate immune response. Uropathogens may form these intracellular biofilms to multiply unhindered within the protected niche of the urothelial cell and even escape antibiotic penetration. Further studies need to be done to determine which uropathogens, including other K. pneumoniae isolates, are able to utilize an intracellular niche during acute bladder infection.

UPEC IBCs are transient in nature; however, UPEC has the ability to form long-lasting QIRs that can seed recurrent infection (46). These QIRs consist of bacterial rosettes within Lamp-1-positive endocytic vesicles. This study did not analyze long-term reservoir formation by K. pneumoniae. Future studies are needed to determine if K. pneumoniae can form QIRs and if these reservoirs can seed recurrent infection.

While it is clear that the presence of FimK inhibits type 1 pilation in K. pneumoniae, the mechanism of this inhibition is not known. FimK does contain an EAL domain, named after conserved residues, which has been implicated in the cleavage of the second messenger molecule, cyclic di-GMP (8, 58, 60). Loss of FimK may lead to higher levels of cyclic di-GMP, which has been implicated in biofilm formation, production of adhesive surface structures, and inhibition of motility (18, 34, 61). Further studies are needed to determine if FimK is an active phosphodiesterase with the ability to cleave cyclic di-GMP and how this second messenger may influence expression of type 1 pili in K. pneumoniae. FimK may be acting exclusively on the expression of type 1 pili, or FimK may also affect the expression of other adhesins or virulence factors in K. pneumoniae that may play a role in UTI. The ability of FimK to decrease type 1 pilus-dependent biofilm formation in UTI89 implies that it acts on a regulatory network affecting type 1 pilation that is conserved between K. pneumoniae and E. coli.

It is not clear why K. pneumoniae is programmed to keep type 1 pili primarily in the phase-OFF orientation. While type 1 pili have been shown to be important in cystitis, perhaps the presence of type 1 pili is detrimental for Klebsiella in other environments or conditions. UPEC type 1 pili have been shown to switch to a phase-OFF state in the kidney (56). Klebsiella may have evolved to be primarily a kidney pathogen without the need for high levels of type 1 pili in this niche. Type 1 pili may be antigenic in the lung or gut and may lead to K. pneumoniae clearance. Additionally, while capsule is an essential virulence factor for K. pneumoniae in many environments (2), it has also been shown to impede adhesion to and invasion of bladder epithelial cells (55). It has been noted that type 1 pili and capsule may be inversely expressed or regulated in K. pneumoniae (40), and this may explain the predisposition toward a less-piliated state.

Our studies have demonstrated that the ability to utilize an intracellular niche during UTI is not specific to UPEC alone. Despite being able to progress through an IBC pathway, K. pneumoniae forms fewer IBCs and has lower titers in bladder than UPEC early in infection. These differences are related, in part, to type 1 pilus expression. This work begins to explain the difference in prevalence of E. coli and K. pneumoniae UTIs and emphasizes the importance of type 1 pilus regulatory elements in the ability of uropathogens to infect the urinary tract. Specifically, we have identified a novel regulatory gene in K. pneumoniae, fimK, capable of suppressing IBC and biofilm formation and impeding UTI pathogenesis.

ACKNOWLEDGMENTS

We thank Wendy Beatty for her EM assistance and expertise, Christopher O’Connor for helpful cloning discussions, and Carsten Struve for phase assay advice.

This work was supported by National Institutes of Health Office of Research on Women’s Health: Specialized Center of Research on Sex and Gender Factors Affecting Women’s Health, grant R01 DK64540; National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, grants R01 AI128549, R01 AI48689, and R01 AI50011.

REFERENCES